Market Research Report
Investigation Report on China's Nivolumab Market 2021-2025
|Published by||China Research and Intelligence||Product code||1002607|
|Published||Content info||50 Pages
Delivery time: 1-2 business days
|Investigation Report on China's Nivolumab Market 2021-2025|
|Published: April 23, 2021||Content info: 50 Pages||
Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1, mainly used to treat non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, advanced renal cell carcinoma, and head and neck squamous cell carcinoma. Nivolumab was first developed by Medarex and Ono Pharmaceuticals. In 2009, Bristol-Myers Squibb acquired these two companies and obtained the patent for Nivolumab. Nivolumab was launched in China in 2018. By 2020, Bristol-Myers Squibb Pharma EEIG is the only manufacturer in the Chinese Nivolumab market.
According to CRI's market research, after Nivolumab entered the Chinese market, the sales value of Nivolumab in China increased from CNY9.9 million in 2018 to CNY 43.1 million in 2020. The growth rate in 2020 was 52.2%, which slowed down due to the COVID-19 epidemic. The CAGR of Nivolumab's sales values in China is 108.7 in 2018 to 2020%.
CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Nivolumab will have a recovery growth from 2021 to 2025. Besides, the sales will also increase due to market expansion. Currently, Nivolumab has three approved indications, including non-small cell lung cancer, head and neck squamous cell carcinoma, and gastric adenocarcinoma and gastroesophageal junction cancer. Its fourth indication application is at the approval stage. As the number of approved indications increases, the sales will continue to grow. On the other hand, the usage rate of Nivolumab was lower than that of other PD-1 products that have been included in the national medical insurance catalog. If the medical insurance negotiation for Nivolumab succeeds, the price adjustment can reduce the burden on patients, which will increase its usage rate.